


**BARRETT'S ESOPHAGUS PATIENT REPORT**

Patient:	John Doe	Date of Biopsy Acquisition:	04/12/2016
Date of Birth:	02/10/1975	Date Received:	04/14/2016
Requisition #:	GEI9687781	Date Reported:	04/19/2016
Medical Record #:	GEI0917681	Ordering Institution:	C Clinic
Specimen Type/ID:	Esophageal pinch biopsy	Ordering Physician:	T. Miller, MD
Number of levels/blocks submitted:	1	Submitting Pathologist:	A. Wilson, MD
Number of levels/blocks tested:	1		


**PATIENT RESULTS: TISSUECYPHER RISK SCORE AND RISK CLASS**

**Definitive Risk Score**



**Definitive Risk Class**

**Risk Class: HIGH**  
**5 year Probability 53%**  
*of Progression: (95% C.I. 36, 65)*



**Validated Calculation of Potential for Progression**

**Clinical Experience in Barrett's Esophagus:**

In a multi-institutional validation study involving 366 patients with Barrett's esophagus from four institutions (1), patients with a risk score of 7.5 had a 35% (95% C.I.25, 44) risk of progression to high grade dysplasia or esophageal adenocarcinoma within 5 years.

1. Critchley-Thorne, R.J., et al., A Tissue Systems Pathology Assay for High Risk Barrett's Esophagus, Cancer Epidemiol Biomarkers Prev. 2016 epub ahead of print.

**Submitting Pathologist Reviews and Notates Abnormalities**

<b>Past TissueCypher Scores</b>	Score: N/A Date:	Score: N/A Date:	Score: N/A Date:	Score: N/A Date:
<b>Abnormalities Detected:</b>	Multiple tissue fragments in the submitted case exhibited over-expression of p53 and COX-2 and p16 in epithelial cells, as well as infiltration of the lamina propria by cells expressing CD68, CD45RO1α, and cells co-expressing CD68 and COX-2.			
<b>Additional Comments:</b>	A.Wilson, MD: Quality assessments passed. Reviewed whole slide images provided by Cernostics, which were consistent with the biomarker abnormalities described and the high risk class reported for this case.			

**5-Year Probability of Progression**

**TISSUECYPHER® BARRETT'S ESOPHAGUS ASSAY DESCRIPTION**

The TissueCypher® Barrett's Assay uses quantitative image analysis to measure the expression of 9 biomarkers and tissue morphology in whole slide digital images of labeled Barrett's esophagus biopsies. A risk score for progression to high grade dysplasia or esophageal adenocarcinoma is generated from the image analysis results. The risk score ranges from 0-10, with 0 indicating lowest risk and 10 indicating highest risk. The risk score is independent of clinical variables, including pathologic diagnosis.

The TissueCypher® Barrett's Assay was developed and its performance characteristics determined by Cernostics, Inc. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test is used for clinical purposes and should not be regarded as investigational or for research. This test has not been reviewed by the Food and Drug Administration (FDA). The results provided here are adjunctive to the ordering physician's workup for patients with Barrett's esophagus.

**Laboratory Director:** Jess Savala Jr., M.D.  
**CLIA#:** 39D2110302  
**Email:** customer.service@cernostics.com

The TissueCypher® Barrett's Esophagus Assay is available exclusively through the Cernostics state-of-the-art diagnostic service laboratory in Pittsburgh, PA. Our expert technicians provide a rapid 5-day turnaround for your patient's biopsy samples.

**To order or obtain additional information: please call 412 828-0900 or visit cernostics.com/tissuecypher**